Comparison of inhaled albuterol powder and aerosol in asthma

Edwin Bronsky, Gerald A. Bucholtz, William W. Busse, Paul Chervinsky, John Condemi, Mohammed A. Ghafouri, Leonard Hudson, S. Lakshminarayan, Richard Lockey, Marshall E. Reese, Stephen Israel Rennard, Allen Segal, Laurence Smolley, Sheldon Spector, John J. Stablein, Andre Van As, Archie Wilson

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

In this multicenter, randomized, double-blind study comparing the efficacy and safety of aerosolized albuterol with the dry powder formulation, 231 patients with chronic reversible obstructive airway disease were randomly allocated to receive either placebo albuterol aerosol followed immediately by active albuterol powder (200 μg) or active albuterol aerosol (two puffs, 180 μg) followed immediately by placebo lactose powder four times a day for a period of 12 weeks. No statistically significant differences were found between the powder and aerosol formulations with respect to pulmonary function, length of time mean FEV1 remained ≥15% above baseline, physicians' assessments of patients' clinical response, or patients' subjective symptom scores. There were also no significant differences between treatment groups in cardiovascular effects, laboratory values, or adverse events. Among patients who expressed a preference for one of the delivery systems, half preferred using the powder. Results of this study demonstrate that 200 μg of albuterol powder is as safe and effective as 180 μg of albuterol aerosol.

Original languageEnglish (US)
Pages (from-to)741-747
Number of pages7
JournalThe Journal of Allergy and Clinical Immunology
Volume79
Issue number5
DOIs
StatePublished - Jan 1 1987

Fingerprint

Albuterol
Aerosols
Powders
Asthma
Placebos
Lactose
Double-Blind Method
Chronic Obstructive Pulmonary Disease
Physicians
Safety
Lung

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Bronsky, E., Bucholtz, G. A., Busse, W. W., Chervinsky, P., Condemi, J., Ghafouri, M. A., ... Wilson, A. (1987). Comparison of inhaled albuterol powder and aerosol in asthma. The Journal of Allergy and Clinical Immunology, 79(5), 741-747. https://doi.org/10.1016/0091-6749(87)90205-3

Comparison of inhaled albuterol powder and aerosol in asthma. / Bronsky, Edwin; Bucholtz, Gerald A.; Busse, William W.; Chervinsky, Paul; Condemi, John; Ghafouri, Mohammed A.; Hudson, Leonard; Lakshminarayan, S.; Lockey, Richard; Reese, Marshall E.; Rennard, Stephen Israel; Segal, Allen; Smolley, Laurence; Spector, Sheldon; Stablein, John J.; Van As, Andre; Wilson, Archie.

In: The Journal of Allergy and Clinical Immunology, Vol. 79, No. 5, 01.01.1987, p. 741-747.

Research output: Contribution to journalArticle

Bronsky, E, Bucholtz, GA, Busse, WW, Chervinsky, P, Condemi, J, Ghafouri, MA, Hudson, L, Lakshminarayan, S, Lockey, R, Reese, ME, Rennard, SI, Segal, A, Smolley, L, Spector, S, Stablein, JJ, Van As, A & Wilson, A 1987, 'Comparison of inhaled albuterol powder and aerosol in asthma', The Journal of Allergy and Clinical Immunology, vol. 79, no. 5, pp. 741-747. https://doi.org/10.1016/0091-6749(87)90205-3
Bronsky E, Bucholtz GA, Busse WW, Chervinsky P, Condemi J, Ghafouri MA et al. Comparison of inhaled albuterol powder and aerosol in asthma. The Journal of Allergy and Clinical Immunology. 1987 Jan 1;79(5):741-747. https://doi.org/10.1016/0091-6749(87)90205-3
Bronsky, Edwin ; Bucholtz, Gerald A. ; Busse, William W. ; Chervinsky, Paul ; Condemi, John ; Ghafouri, Mohammed A. ; Hudson, Leonard ; Lakshminarayan, S. ; Lockey, Richard ; Reese, Marshall E. ; Rennard, Stephen Israel ; Segal, Allen ; Smolley, Laurence ; Spector, Sheldon ; Stablein, John J. ; Van As, Andre ; Wilson, Archie. / Comparison of inhaled albuterol powder and aerosol in asthma. In: The Journal of Allergy and Clinical Immunology. 1987 ; Vol. 79, No. 5. pp. 741-747.
@article{769a989928b8403da3e01f5e60eda6d8,
title = "Comparison of inhaled albuterol powder and aerosol in asthma",
abstract = "In this multicenter, randomized, double-blind study comparing the efficacy and safety of aerosolized albuterol with the dry powder formulation, 231 patients with chronic reversible obstructive airway disease were randomly allocated to receive either placebo albuterol aerosol followed immediately by active albuterol powder (200 μg) or active albuterol aerosol (two puffs, 180 μg) followed immediately by placebo lactose powder four times a day for a period of 12 weeks. No statistically significant differences were found between the powder and aerosol formulations with respect to pulmonary function, length of time mean FEV1 remained ≥15{\%} above baseline, physicians' assessments of patients' clinical response, or patients' subjective symptom scores. There were also no significant differences between treatment groups in cardiovascular effects, laboratory values, or adverse events. Among patients who expressed a preference for one of the delivery systems, half preferred using the powder. Results of this study demonstrate that 200 μg of albuterol powder is as safe and effective as 180 μg of albuterol aerosol.",
author = "Edwin Bronsky and Bucholtz, {Gerald A.} and Busse, {William W.} and Paul Chervinsky and John Condemi and Ghafouri, {Mohammed A.} and Leonard Hudson and S. Lakshminarayan and Richard Lockey and Reese, {Marshall E.} and Rennard, {Stephen Israel} and Allen Segal and Laurence Smolley and Sheldon Spector and Stablein, {John J.} and {Van As}, Andre and Archie Wilson",
year = "1987",
month = "1",
day = "1",
doi = "10.1016/0091-6749(87)90205-3",
language = "English (US)",
volume = "79",
pages = "741--747",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Comparison of inhaled albuterol powder and aerosol in asthma

AU - Bronsky, Edwin

AU - Bucholtz, Gerald A.

AU - Busse, William W.

AU - Chervinsky, Paul

AU - Condemi, John

AU - Ghafouri, Mohammed A.

AU - Hudson, Leonard

AU - Lakshminarayan, S.

AU - Lockey, Richard

AU - Reese, Marshall E.

AU - Rennard, Stephen Israel

AU - Segal, Allen

AU - Smolley, Laurence

AU - Spector, Sheldon

AU - Stablein, John J.

AU - Van As, Andre

AU - Wilson, Archie

PY - 1987/1/1

Y1 - 1987/1/1

N2 - In this multicenter, randomized, double-blind study comparing the efficacy and safety of aerosolized albuterol with the dry powder formulation, 231 patients with chronic reversible obstructive airway disease were randomly allocated to receive either placebo albuterol aerosol followed immediately by active albuterol powder (200 μg) or active albuterol aerosol (two puffs, 180 μg) followed immediately by placebo lactose powder four times a day for a period of 12 weeks. No statistically significant differences were found between the powder and aerosol formulations with respect to pulmonary function, length of time mean FEV1 remained ≥15% above baseline, physicians' assessments of patients' clinical response, or patients' subjective symptom scores. There were also no significant differences between treatment groups in cardiovascular effects, laboratory values, or adverse events. Among patients who expressed a preference for one of the delivery systems, half preferred using the powder. Results of this study demonstrate that 200 μg of albuterol powder is as safe and effective as 180 μg of albuterol aerosol.

AB - In this multicenter, randomized, double-blind study comparing the efficacy and safety of aerosolized albuterol with the dry powder formulation, 231 patients with chronic reversible obstructive airway disease were randomly allocated to receive either placebo albuterol aerosol followed immediately by active albuterol powder (200 μg) or active albuterol aerosol (two puffs, 180 μg) followed immediately by placebo lactose powder four times a day for a period of 12 weeks. No statistically significant differences were found between the powder and aerosol formulations with respect to pulmonary function, length of time mean FEV1 remained ≥15% above baseline, physicians' assessments of patients' clinical response, or patients' subjective symptom scores. There were also no significant differences between treatment groups in cardiovascular effects, laboratory values, or adverse events. Among patients who expressed a preference for one of the delivery systems, half preferred using the powder. Results of this study demonstrate that 200 μg of albuterol powder is as safe and effective as 180 μg of albuterol aerosol.

UR - http://www.scopus.com/inward/record.url?scp=0023224998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023224998&partnerID=8YFLogxK

U2 - 10.1016/0091-6749(87)90205-3

DO - 10.1016/0091-6749(87)90205-3

M3 - Article

VL - 79

SP - 741

EP - 747

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 5

ER -